Topoisomerase I inhibition: a new target or new missiles?
Verweij
J
J
Schellens
J H
JH
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D015195:Drug Design; D004357:Drug Synergism; D006801:Humans; D000077146:Irinotecan; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D059004:Topoisomerase I Inhibitors; D019772:Topotecan
D000972:Antineoplastic Agents, Phytogenic; D009363:Neoplasm Proteins; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D019772:Topotecan; D002166:Camptothecin